Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Employment/Membership › Details

Almirall–Nazzi G: management, 202105– CEO before Teva Pharmaceuticals + AstraZeneca + GSK + Eli Lilly

 

Period Period 2021-05-01
Organisations Organisation Almirall S.A. (Spanish Stock Exchange: ALM)
  Group Almirall (Group)
  Organisation 2 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
  Group Teva (Group)
Products Product dermatic
  Product 2 pharmaceutical
Persons Person Nazzi, Gianfranco (Almirall 202105– CEO before Teva Pharmaceuticals + AstraZeneca + GSK + Eli Lilly)
  Person 2 Guenter, Peter (Almirall 201710–202012 CEO before Sanofi for 22 years before SmithKline + Ciba-Geigy LEFT 12/20)
     

Almirall S.A.. (2/3/21). "Press Release: Almirall Announces Gianfranco Nazzi as New CEO".

> Gianfranco Nazzi brings broad international experience from a distinguished career in Pharma

> Mr. Nazzi will join Almirall as Chief Executive Officer on May 1, 2021


Almirall, S.A. (BME:ALM), a global biopharmaceutical company focused on Medical Dermatology based in Barcelona, announced today that the Board of Directors have approved the appointment of Mr. Gianfranco Nazzi as CEO and Executive Director of the Board of Directors effective May 1, 2021.

Mr. Nazzi joins Almirall from Teva Pharmaceuticals Industries Ltd, where he has most recently been serving as Executive Vice President of the International Markets Region and as a member of the Teva Executive Committee. While at Teva over the past seven years, he has held roles of increasing responsibility and geographic scope based in Israel and the Netherlands. He held the position of Senior Vice President Specialty Medicines Europe and President and CEO Growth Markets Region. Prior to Teva Mr. Nazzi held a variety of senior positions in Astra Zeneca, GSK and Eli Lilly in commercial and General Management roles based in the UK, Italy, Serbia and the US.

“I´m very pleased to announce that the Board of Directors have agreed to appoint Gianfranco Nazzi. Mr. Nazzi is a trusted leader in the Pharma industry and brings with him a wealth of experience in areas key to the success and growth of Almirall, in US, Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level”, said Jorge Gallardo, Chairman of the Board and President of Almirall.

“I am really excited to join Almirall and its talented team of professionals. The company’s focus on putting patients at the center of all that they do is inspiring and I am sure that I will be able to continue to support them and provide them with novel and value added solutions and treatments to improve their lives. I am committed to this mission and I know that, together with the team, we will achieve great milestones in the near future”, stated Gianfranco Nazzi.

Gianfranco Nazzi is Italian and holds a degree in Economics and Banking Sciences from the University of Udine and a Master’s Degree of Business Administration from the Bocconi University of Milan.

Mr. Nazzi will take over the CEO duties from Mike McClellan, who at the beginning of the year was appointed interim CEO in addition to his role as CFO after the company’s former Chief Executive Officer, Peter Guenter, left Almirall on December 31st to pursue other professional endeavors.


About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX 35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com

   
Record changed: 2021-02-23

Advertisement

Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px

More documents for Almirall (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top